Abstract: An apparatus and method for switching between different types of paging using separate control registers and without disabling paging. For example, one embodiment of a processor comprises: a first control register to store a first base address of a first paging structure associated with a first type of paging having a first number of paging structure levels; a second control register to store a second base address of a second paging structure associated with a first type of paging having a second number of paging structure levels greater than the first number of paging structure levels; page walk circuitry to select either the first base address from the first control register or the second base address from the second control register responsive to a first address translation request, the selection based on a characteristic of program code initiating the address translation request.

Abstract: A variety of methods are disclosed, including, in one embodiment, a method of making crosslinked aromatic resin beads comprising: contacting a linker agent and a catalyst with an aromatic feedstock at a first temperature effective to react the linker agent with molecules in the aromatic feedstock to form a pre-polymer mixture; combining the pre-polymer mixture with an antisolvent; agitating the pre-polymer mixture and the antisolvent; and heating the pre-polymer mixture and antisolvent to a second temperature to react the pre-polymer mixture to form crosslinked aromatic resin beads, wherein the pre-polymer mixture is dispersed as droplets in the anti solvent.

Abstract: This disclosure relates to a heat transfer fluid having at least one first ester that is partially esterified, and at least one second ester that is fully esterified. The heat transfer fluid has a flash point from about 125° C. to about 225° C. as determined by ASTM D-93, and a kinematic viscosity (KV100) from about 1 to about 5 at 100° C. as determined by ASTM D-445. The at least one first ester and the at least one second ester are present in an amount such that, as the flash point and thermal conductivity of the heat transfer fluid are increased, the kinematic viscosity (KV100) of the heat transfer fluid is decreased or essentially maintained. This disclosure also relates to a method for increasing flash point and thermal conductivity, while decreasing or essentially maintaining viscosity, of a heat transfer fluid by using the heat transfer fluid.

Abstract: This disclosure relates to a lubricating oil having a lubricating oil base stock as a major component, and one or more lubricating oil additives as a minor component. The lubricating oil base stock has at least one first ester that is partially esterified, and at least one second ester that is fully esterified. The lubricating oil has a flash point from about 125° C. to about 225° C. as determined by ASTM D-93, and a kinematic viscosity (KV100) from about 1 to about 5 at 100° C. as determined by ASTM D-445. The at least one first ester and the at least one second ester are present in an amount such that, as the flash point of the lubricating oil is increased, the kinematic viscosity (KV100) of the lubricating oil is decreased or maintained. This disclosure also relates to a method for increasing flash point, while decreasing or maintaining viscosity, of a lubricating oil in an engine or other mechanical component lubricated with the lubricating oil by using the lubricating oil.

Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.

Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.

Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.

Abstract: Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.